NASDAQ: ACTUActuate Therapeutics Inc Stock
$1.96+0.01 (+0.51%)
Updated Jun 25, 2026
ACTU Price
$1.96
Fair Value Price
$0.61
Market Cap
$46.89M
52 Week Low
$1.58
52 Week High
$9.22
P/E
-2.02x
P/B
12.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.54M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.36
Operating Cash Flow
-$20M
Beta
1.11
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ACTU Overview
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACTU's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ACTU news, forecast changes, insider trades & much more!
ACTU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACTU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACTU ($1.96) is overvalued by 223.05% relative to our estimate of its Fair Value price of $0.61 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACTU ($1.96) is not significantly undervalued (223.05%) relative to our estimate of its Fair Value price of $0.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACTU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACTU due diligence checks available for Premium users.
Valuation
ACTU fair value
Fair Value of ACTU stock based on Discounted Cash Flow (DCF)
Price
$1.96
Fair Value
$0.61
Overvalued by
223.05%
ACTU ($1.96) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACTU ($1.96) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACTU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACTU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.02x
Industry
15.39x
Market
8.79x
ACTU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.39x
Industry
5.26x
ACTU is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACTU's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.6M
Profit Margin
0%
ACTU's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.9M
Liabilities
$5.1M
Debt to equity
1.36
ACTU's short-term assets ($8.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACTU's short-term assets ($8.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACTU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
$0.0
Financing
-$8.1k
ACTU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACTU vs Biotech Stocks
Actuate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.